Variations of p53 in cultured fibroblasts of patients with lung cancer who have a presumed genetic predisposition

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 22, Issue 3, 1999, Pages 278-282

  Auer, H ^a   Warncke, K ^a   Nowak, D ^b   Koops, F ^c   Jaeger, U ^a   Kurzbauer, R ^d   Ruediger, H W ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF HAMBURG   (Germany)

^d RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

Author keywords

Li Fraumeni syndrome; Lung cancer genetics; P53 Tumor suppressor gene

Indexed keywords

ASPARAGINE; DNA; PROTEIN P53; SERINE;

ADULT; AGED; ARTICLE; FEMALE; FIBROBLAST CULTURE; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; HUMAN CELL; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM; SKIN FIBROBLAST; SYNDROME; TUMOR SUPPRESSOR GENE;

EID: 0033503269     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199906000-00013     Document Type: Article

References (46)

1. Lynch HT, Fusaro RM, Lynch J. Hereditary cancer in adults. Cancer Detect Prev 1995;19:219-33.
2. Malkin D. p53 and the Li-Fraumeni syndrome. Biochim Biophys Acta 1994;1198:197-213.
3. Devereux TR, Taylor JA, Barrett JC. Molecular mechanisms of lung cancer. Interaction of environmental and genetic factors. Chest 1996;109(suppl 3):14s-19s.
4. Rüdiger HW, Nowak D, Hartmann K, Cerutti P. Enhanced formation of benzo(a)pyrene: DNA adducts in monocytes of patients with a presumed predisposition to lung cancer. Cancer Res 1985; 45:5890-4.
5. Nowak D, Schmidt-Preuss U, Jörres R, et al. Formation of DNA adducts and water-soluble metabolites of benzo(a)pyren in human monocytes is genetically controlled. Int J Cancer 1988;41:169-73.
6. Law MR, Hetzel MR, Idel JR. Debrisoquine metabolism and genetic predisposition to lung cancer. Br J Cancer 1989;59:686-7.
7. Shaw GL, Falk RT, Deslauriers J, et al. Debrisoquine metabolism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 1995;4: 41-8.
8. Hamada GS, Sugimura H, Suzuki I, et al. The heme-binding region polymorphism of cytochrome P450IA1 (CypIA1), rather than the Rsal polymorphism of IIE1 (CypIIE1), is associated with lung cancer in Rio de Janeiro. Cancer Epidemiol Biomarkers Prev 1995;4:63-7.
9. Oyama T, Kawamoto T, Mizoue T, et al. Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer in relation to p53 gene mutation. Anticancer Res 1997;17:583-7.
10. Hirvonen A, Husgafvel Pursiainen K, Karjalainen A, Anttila S, Vainio H. Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prev 1992;1:485-9.
11. Seidegard J, Pero RW, Markowitz MM, et al. Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: a follow-up study. Carcinogenesis 1990;11:33-6.
12. Zhong S, Howie AF, Ketterer B, et al. Glutathione S-transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis 1991; 12:1533-7.
13. Sugimura H, Caporaso NE, Modali RV, et al. Association of rare alleles of the Harvey ras protooncogene locus with lung cancer. Cancer Res 1990;50:1857-62.
14. Kawashima K, Shikama H, Imoto K, et al. Close correlation between restriction fragment length polymorphism of the L-MYC gene and metastasis of human lung cancer to the lymph nodes and other organs. Proc Natl Acad Sci USA 1988;85:2353-6.
15. Weston A, Caporaso NE, Perrin LS, et al. Relationship of H-ras-1, L-myc, and p53 polymorphisms with lung cancer risk and prognosis. Environ Health Perspect 1992;98:61-7.
16. Tamai S, Sugimura H, Caporaso NE, et al. Restriction fragment length polymorphism analysis of the L-myc gene locus in a case-control study of lung cancer. Int J Cancer 1990;46:411-5.
17. Kawajiri K, Nakachi K, Imai K, et al. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 1993;14:1085-9.
18. Jin X, Wu X, Roth JA, et al. Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis 1995;16:2205-8.
19. Weston A, Perrin LS, Forrester K, et al. Allelic frequency of a p53 polymorphism in human lung cancer. Cancer Epidemiol Biomarkers Prev 1992;1:481-3.
20. Lynch HT, Katz DA, Bogard PJ, Lynch JF. The sarcoma, breast cancer, lung cancer, and adrenocortical carcinoma syndrome revisited. Childhood cancer. Am J Dis Child 1985;139:134-6.
21. Ledbetter SA and Nelson DL. Genome amplification using primers directed to interspersed repetitive sequences (IRS-PCR). In: McPherson MJ, Quirke P, Taylor GR, eds. PCR: a practical approach. Oxford: Oxford University Press, 1994:107-19.
22. Sameshima Y, Matsuno Y, Hirohashi S, et al. Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma. Oncogene 1992;7:451-7.
23. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature 1989;339:237-8.
24. Mohabeer AJ, Hiti AL, Martin WJ. Non-radioactive single strand conformation polymorphism (SSCP) using the Pharmacia 'Phast-System'. Nucleic Acids Res 1991;19:3154-3400.
25. Maniatis T, Fritsch EF, Sambrook J. Molecular cloning. A laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Press, 1982.
26. De la Calle Martin O, Fabregat V, Romero M, Soler J, Vives J, Yague J. AccII polymorphism of the p53 gene. Nucleic Acids Res 1990;18:4963.
27. Beckman G, Birgander R, Sjalander A, et al. Is p53 polymorphism maintained by natural selection? Hum Hered 1994;44:266-70.
28. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-27.
29. Sarkar G, Yoon HS, Sommer SS. Screening for mutations by RNA single-strand conformation polymorphism (rSSCP): comparison with DNA-SSCP. Nucleic Acids Res 1992;20:871-8.
30. Ushijima T, Hosoya Y, Suzuki T, et al. A rapid method for detection of mutations in the lacI gene using PCR-single strand conformation polymorphism analysis: demonstration of its high sensitivity. Mutat Res 1995;334:283-92.
31. Birgander R, Sjalander A, Rannug A, et al. P53 polymorphisms and haplotypes in lung cancer. Carcinogenesis 1995;16:2233-6.
32. Felix CA, Brown DL, Mitsudomi T, et al. Polymorphism at codon 36 of the p53 gene. Oncogene 1994;9:327-8.
33. Carbone D, Chiba I, Mitsudomi T. Polymorphism at codon 213 within the p53 gene. Oncogene 1991;6:1691-2.
34. D'Agostini F, Fronza G, Campomenosi P, et al. Cancer biomarkers in human atherosclerotic lesions: no evidence of p53 involvement. Cancer Epidemiol Biomarkers Prev 1995;4:111-5.
35. Ahuja HG, Testa MP, Cline MJ. Variation in the protein coding region of the human p53 gene. Oncngene 1990;5:1409-10.
36. Felley Bosco E, Weston A, Cawley HM, et al. Functional studies of a germ-line polymorphism at codon 47 within the p53 gene. Am J Hum Genet 1993;53:752-9.
37. Toguchida J, Yamaguchi T, Ritchie B, et al. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 1992;52:6194-9.
38. Gutierrez MI, Bhatia KG, Barreiro C, et al. A de novo p53 germline mutation affecting codon 151 in a six-year-old child with multiple tumors. Hum Mol Genet 1994;3:2247-8.
39. Strauss EA, Hosler MR, Herzog P, et al. Complex replication error causes p53 mutation in a Li-Fraumeni family. Cancer Res 1995; 55:3237-41.
40. Wagner J, Portwine C, Rabin K, et al. High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst 1994;86:1707-10.
41. Li YJ, Sanson M, Hoang Xuan K, et al. Incidence of germ-line p53 mutations in patients with gliomas. Int J Cancer 1995;64:383-7.
42. Frebourg T, Barbier N, Van YX, et al. Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet 1995; 56:608-15.
43. Kleihues P, Schauble B, zur Hausen A, et al. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 1997;150:1-13.
44. Hollstein M, Shomer B, Greenblatt M, et al. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 1996;24:141-6.
45. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994;265:346-55.
46. Chiba I, Takahashi T, Nau MM, et al. Mutations in the p53 gene are frequent in primary, resected non-small-cell lung cancer. Lung Cancer Study Group. Oncogene 1990;5:1603-10.